Placental Growth Factor as a Diagnostic Glycoprotein in Preeclampsia
DOI:
https://doi.org/10.24237/ASJ.02.02.757BKeywords:
placental growth factor, preeclampsia, proteinuria, blood pressure.Abstract
Angiogenic factor imbalance, such as that caused by placental growth factor (PLGF), is a feature of preeclampsia. However, the connection amony PLGF, clinical, laboratory indicators and the severity of preeclampsia is not entirely understood. Ninety subjects were incorporated in this study (The age range 17-40years),( 30 ) were healthy pregnant with mean age (26.57±1.07 ). (30) Mild Preeclampsia cases with mean age (30.42±0.78) and (30) sever PE with mean age (33.32±1.09) wherever all women were more than 20 weeks of pregnancy. Mean blood pressure and level of proteinuria were used as indicators of the severity of the disease. ELISA was used to measure the levels of PLGF in the serum. Serum lipid profile were measured by enzymatic methods. The qualitative dip-stick technique was used to assess the amount of urine protein. A substantial difference between the PE group's serum PLGF concentration and that of the healthy subjects (p= 0.001) could be seen. Serum PLGF concentrations of patients with mild PE and those with severe PE differed significantly. Additionally, there were strong positive relationships between the serum PLGF concentration and the systolic BP and proteinuria serum PLGF levels, biochemical indicators, and other factors, however, did not significantly correlate. The diagnostic accuracy in distinguishing PE from the healthy patient group was good thanks to the excellent area under the curve (AUC = 0.83, p = 0.0001) In conclusion, Levels of PLGF in area of PE patients were decreaed. PLGF was significantly correlated with PE patients.
References
T. H. Hung, J. N. Skepper, D. S. Charnock-Jones, Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia, Circ Res., 90(12):1274–81(2002)
Soleymanlou N, Jurisica I, Nevo O, et al. Molecular evidence of placental hypoxia in preeclampsia, J Clin Endocrinol Metab., 90(7),4299–308(2005)
C. A. Turpin, S. A. Sakyi, W. K. Owiredu, Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia, BMC Pregnancy Childbirth, 15(1),189(2015)
S. Y. Kim, H. M. Ryu, J. H. Yang, Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia, J Korean Med Sci., 22(5),873–7(2007)
K. O. Osungbade, O. K. Ige, Public Health Perspectives of Preeclampsia in Developing Countries: Implication for Health System Strengthening, Journal of Pregnancy, 2011,4810956(2011)
J. Wilkinson, G. Cole, Preeclampsia knowledge among women in Utah, Hypertens Pregnancy, 37(1),18–24(2018)
D. Raymond, E.Peterson, A critical review of early-onset and late-onset preeclampsia, Obstet Gynecol Surv, 66(8),497–506(2011)
R. J. Levine, S. E. Maynard, C. Qian, K. H. Lim, L. J. England, K. F. Yu, E. F. Schisterman, R. Thadhani, B. P. Sachs, F. H. Epstein, B. M. Sibai , V. P. Sukhatme, S. A. Karumanchi, Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med., 350:672–683(2004)
R. J. Levine, C. Lam, C. Qian, K. F. Yu, S. E. Maynard, B. P. Sachs, B. M. Sibai, F. H. Epstein, R. Romero, R. Thadhani, S. A. Karumanchi, CPEP Study Group, Soluble endoglin and other circulating antiangiogenic factors in preeclampsia, N Engl J Med., 355,992–1005(2006)
A. Leaños-Miranda, I. Campos-Galicia, I. Isordia-Salas, R. Rivera-Leaños, J. F. Romero-Arauz, J. A. Ayala-Méndez, A. Ulloa-Aguirre, Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia, J Hypertens, 30,2173–2181(2012)
S. Rana, C. E. Powe, S. Salahuddin, S. Verlohren, F. H. Perschel, R. J. Levine, K. H. Lim, J. B. Wenger, R. Thadhani, S. A. Karumanchi, Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia, Circulation, 125,911–919(2012)
A. Leaños-Miranda, I. Campos-Galicia, K. L. Ramírez-Valenzuela, Z. L. Chinolla-Arellano, I. Isordia-Salas, Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia, Hypertension, 61,1118–1125(2013)
A. Leaños-Miranda, F. Méndez-Aguilar, K. L. Ramírez-Valenzuela, Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes, Medicine (Baltimore), 96:e6005e (2017)
H. Zeisler, E. Llurba, F. Chantraine, M. Vatish, AC. Staff, M. Sennström, M. Olovsson, S. P. Brennecke, H. Stepan, D. Allegranza, P. Dilba, M. Schoedl, M. Hund, S. Verlohren, Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia, N Engl J Med., 374,13–22(2016)
B. C. Young, R. J. Levine, S. A. Karumanchi, Pathogenesis of preeclampsia, Annual Review of Pathology, 5,173-192(2010)
B. Sibai, G. Dekker, M. Kupferminc, Pre-eclampsia, Lancet Feb 26-,365(9461),785-799(2005)
S. E. Maynard, J. Y. Min, J. Merchan, K. H. Lim, J. Li, S. Mondal, T. A. Libermann, J. P. Morgan, F. W. Sellke, I. E. Stillman, F. H. Epstein, V. P. Sukhatme, S. A. Karumanchi, Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J Clin Invest, Mar,111(5),649-658(2003)
M. Autiero, A. Luttun, M. Tjwa, P. Carmeliet, Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders, J Thromb Haemost, 1(7),1356-1370(2003)
S. De Falco, The discovery of placenta growth factor and its biological activity, Exp Mol Med, Jan 31,44(1),1-9(2012)
C. J. Robinson, D. D. Johnson, Soluble endoglin as a second-trimester marker for preeclampsia, Am J Obstet Gynecol, 197, 174.e171–175(2007)
C. Li, R. Issa, P. Kumar, I. N. Hampson, J. M. Lopez-Novoa, CD105 prevents apoptosis in hypoxic endothelial cells, J Cell Sci, 116, 2677–2685(2003)
M. Jerkic, J. V. Rivas-Elena, M. Prieto, R. Carro´n, F. Sanz-Rodrı ´guez, Endoglin regulates nitric oxide-dependent vasodilatation, FASEB J,18, 609–611(2004)
S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto, Soluble endoglin contributes to the pathogenesis of preeclampsia, Nat Med, 12, 642–649(2006)
A. Leaños-Miranda, I. Campos-Galicia, K. L. Ramírez-Valenzuela, Z. L. Chinolla-Arellano, I. Isordia-Salas, Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia, Hypertension, 61,1118–1125(2013)
A. Leaños-Miranda, F. Méndez-Aguilar, K. L. Ramírez-Valenzuela, Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes, Medicine (Baltimore), 96:e6005e(2017)
L. O. Perucci, K. B. Gomes, L. G. Freitas, L. C. Godoi, P. N. Alpoim, M. B. Pinheiro, A. S. Miranda, A. L. Teixeira, L. M. Dusse, L. P.Sousa, Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia, PLoS One, 9,e97632(2014)
S. Rana, A. S. Cerdeira, J. Wenger, S. Salahuddin, K. H. Lim, S. J. Ralston, R. I. Thadhani, S. A. Karumanchi, Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia, PLoS One, 7,e48259(2012)
R. Troisi, K. Braekke, N. K. Harsem, M. Hyer, R. N. Hoover, Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies, Am J Obstet Gynecol, 199, 653,e651–610(2008)
S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto, Soluble endoglin contributes to the pathogenesis of preeclampsia, Nat Med, 12, 642–649(2006)
M. Tjwa, A. Luttun, M. Autiero, P. Carmeliet, VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis, Cell Tissue Res, 314, 5–14(2003)
H. Masuyama, H. Nakatsukasa, N. Takamoto, Y. Hiramatsu, Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia, J Clin Endocrinol Metab, 92, 2672–2679(2007)
A. De Vivo, G. Baviera, D. Giordano, G. Todarello, F. Corrado, R. D'anna, Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia, Acta obstetricia et gynecologica scandinavica, 87(8), 837-842(2008)
J. H. Lim, S. Y. Kim, S. Y. Park, J. H. Yang, M. Y. Kim, H. M. Ryu, Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors, Obstetrics and gynecology, 111(6), 1403-1409(2008)
M. U. Baumann, N. A. Bersinger, M. G. Mohaupt, L. Raio, S. Gerber, D. V. Surbek, Firs-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 ats first-trimester markers for late-onset preeclampsia, American journal of obstetrics and gynecology 199(3), 266, e1-e6(2008)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 CC BY 4.0
This work is licensed under a Creative Commons Attribution 4.0 International License.
